NCT01997164View on ClinicalTrials.gov

"Study of Intravitreal (IVT) REGN910-3 and IVT REGN910 in Patients With Either Neovascular (Wet) Age Related Macular Degeneration (AMD) or Diabetic Macular Edema (DME)"

PHASE1CompletedINTERVENTIONAL

Enrollment

Participants

Timeline

Start Date

November 30, 2014

Primary Completion Date

October 31, 2015

Study Completion Date

October 31, 2015

Conditions

Neovascular Age-Related Macular DegenerationDiabetic Macular Edema

Interventions

DRUG

REGN910-3

DRUG

REGN910

DRUG

Intravitreal Aflibercept Injection (IAI)

Trial Locations (5)

Unknown

Beverly Hills

Winter Haven

Boston

West Columbia

Abilene

All Listed Sponsors

lead

Regeneron Pharmaceuticals

INDUSTRY

NCT01997164 - "Study of Intravitreal (IVT) REGN910-3 and IVT REGN910 in Patients With Either Neovascular (Wet) Age Related Macular Degeneration (AMD) or Diabetic Macular Edema (DME)" | Biotech Hunter | Biotech Hunter